ClinicalTrials.Veeva

Menu

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (BLISS-76)

H

Human Genome Sciences

Status and phase

Completed
Phase 3

Conditions

Systemic Lupus Erythematosus

Treatments

Drug: Belimumab 1 mg/kg
Drug: Belimumab 10 mg/kg
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00410384
110751 (Other Identifier)
BLISS-76
HGS1006-C1056

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.

Enrollment

819 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Clinical diagnosis of SLE by ACR criteria.
  • Active SLE disease.
  • Autoantibody-positive.
  • On stable SLE treatment regimen.

Key Exclusion Criteria:

  • Pregnant or nursing
  • Have received treatment with any B cell targeted therapy.
  • Have received treatment with a biological investigational agent in the past year.
  • Have received IV cyclophosphamide within 180 days of Day 0.
  • Have severe lupus kidney disease.
  • Have active central nervous system (CNS) lupus.
  • Have required management of acute or chronic infections within the past 60 days.
  • Have current drug or alcohol abuse or dependence.
  • Have a historically positive test or test positive at screening for HIV, hepatitis B, or hepatitis C.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

819 participants in 3 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
Placebo
Treatment:
Drug: Placebo
Belimumab 1 mg/kg
Experimental group
Description:
Belimumab 1 mg/kg
Treatment:
Drug: Belimumab 1 mg/kg
Belimumab 10 mg/kg
Experimental group
Description:
Belimumab 10 mg/kg
Treatment:
Drug: Belimumab 10 mg/kg

Trial contacts and locations

146

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems